Amgen Looks To Build On Blincyto Momentum As It Enters A Year Loaded With Milestones
Executive Summary
Three 2015 filings play a key role in the big biotech offsetting expected revenue declines for four legacy products. The biggest test will be the showdown between its PCSK9 inhibitor evolocumab and Sanofi/Regeneron’s competing alirocumab, which is expected to reach market first.
You may also be interested in...
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.
Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
AbbVie Halts Another Trial With I-Mab Antibody, Slashes Deal Size
AbbVie is to terminate the clinical development of lemzoparlimab for myelodysplastic syndrome and acute myelocytic leukemia and will also reduce the size of its 2020 deal with originator I-Mab by $445m, in the latest blow to the Chinese firm.